Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions

NCT04172922 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped IRB suspended and subsequent early termination

Conditions

Vascular Anomaly

Interventions

DRUG: Topical Sirolimus

Sponsor

Nemours Children's Clinic